Introduction: To evaluate the efficacy of Bifiprost® + Serenoa Repens 320 mg versus Serenoa Repens 320 mg alone for the prevention of chronic bacterial prostatitis (CBP) due to enterobacteriaceae. Methods: Between September 2016 and September 2018, 120 patients with CBP at the National Institutes of Health (NIH type II) with recurrent infections due to enterobacteriaceae (Escherichia Coli and Enterococcus faecalis) were enrolled and randomized into 2 groups each to receive Bifiprost® + Serenoa Repens 320 mg (Group A) or Serenoa Repens 320 mg alone (Group B) daily for 24 weeks (after receiving a proper antibiotic treatment with subsequent culture negativization). The primary endpoint was the reduction in the episodes of prostatitis. The secondary endpoint evaluated was the score of the NIH-Chronic Prostatitis Symptom Index (NIH-CPSI). Evaluation was performed at baseline and at 12, 24, and 36 weeks. Results: The patients of the Group A experienced a significantly larger reduction in the prostatitis episodes than the Group B at 24 and 36 weeks, but they did not experience a significantly larger reduction at 12 weeks. After 12 weeks of treatment, the mean NIH-CPSI score was reduced in both groups compared with baselines, but no significant differences were seen between the Group A and Group B. On the contrary, we observed a significant difference in the mean NIH-CPSI score between the 2 groups at 24 and 36 weeks. Conclusion: The association of Bifiprost® and Serenoa Repens 320 mg improves the prevention of the episodes of CBP due to enterobacteriaceae and ameliorates prostatitis-related symptoms after 6 months of therapy. The long-term impact on the entero-urinary route was also seen 3 months after the end of the treatment.

Keywords:
Prostate, Prostatitis, Symptoms, Inflammation, Entero-urinary route, Probiotic
1.
Ooi SL, Pak SC. Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and Its Clinical Implications in Naturopathic Medicine.
J Altern Complement Med
. 2017 Aug;23(8):599–606.
2.
Boltri M, Magri V, Montanari E, Perletti G, Trinchieri A. Computer-Assisted Quantitative Assessment of Prostatic Calcifications in Patients with Chronic Prostatitis.
Urol Int
. 2018;100(4):450–5.
3.
Li X, Jiang T, Liu F, Shao X, Xu Y, Sheng W, et al. Clinical Evaluation of Urine Prostatic Exosomal Protein in the Diagnosis of Chronic Prostatitis.
Urol Int
. 2018;100(1):112–8.
4.
Morgia G, Mucciardi G, Galì A, Madonia M, Marchese F, Di Benedetto A, et al. Treatment of chronic prostatitis/chronic pelvic pain syndrome category IIIA with Serenoa repens plus selenium and lycopene (Profluss) versus S. repens alone: an Italian randomized multicenter-controlled study.
Urol Int
. 2010;84(4):400–6.
5.
Pappas E, Schaich KM. Phytochemicals of cranberries and cranberry products: characterization, potential health effects, and processing stability.
Crit Rev Food Sci Nutr
. 2009 Oct;49(9):741–81.
6.
Blumberg JB, Camesano TA, Cassidy A, Kris-Etherton P, Howell A, Manach C, et al. Cranberries and their bioactive constituents in human health.
Adv Nutr
. 2013;4(6):618–32.
7.
Hisano M, Bruschini H, Nicodemo AC, Srougi M. Cranberries and lower urinary tract infection prevention.
Clinics (São Paulo)
. 2012;67(6):661–8.
8.
Vidlar A, Student V Jr, Vostalova J, Fromentin E, Roller M, Simanek V, et al. Cranberry fruit powder (FlowensTM) improves lower urinary tract symptoms in men: a double-blind, randomized, placebo-controlled study.
World J Urol
. 2016 Mar;34(3):419–24.
9.
Fibbi B, Penna G, Morelli A, Adorini L, Maggi M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia.
Int J Androl
. 2010 Jun;33(3):475–88.
10.
Sato M, Ramarathnam N, Suzuki Y, Ohkubo T, Takeuchi M, Ochi H. Varietal differences in the phenolic content and superoxide radical scavenging potential of wines from different sources.
J Agric Food Chem
. 1996;44(1):37–41.
11.
Bouarab-Chibane L, Forquet V, Lantéri P, Clément Y, Léonard-Akkari L, Oulahal N, et al. Antibacterial Properties of Polyphenols: Characterization and QSAR (Quantitative Structure-Activity Relationship) Models.
Front Microbiol
. 2019 Apr;10:829.
12.
Li AN, Li S, Zhang YJ, Xu XR, Chen YM, Li HB. Resources and biological activities of natural polyphenols.
Nutrients
. 2014 Dec;6(12):6020–47.
13.
Daglia M. Polyphenols as antimicrobial agents.
Curr Opin Biotechnol
. 2012;23(2):174–81.
14.
Potterat O. Goji (Lycium barbarum and L. chinense): Phytochemistry, pharmacology and safety in the perspective of traditional uses and recent popularity.
Planta Med
. 2010 Jan;76(1):7–19.
15.
Li XL, Zhou AG. Evaluation of the antioxidant effects of polysaccharides extracted from Lycium barbarum.
Med Chem Res
. 2007;15(9):471–82.
16.
Li XM, Li XL, Zhou AG. Evaluation of antioxidant activity of the polysaccharides extracted from Lycium barbarum fruits in vitro.
Eur Polym J
. 2007;43(2):488–97.
17.
Piano MD, Carmagnola S, Ballarè M, Balzarini M, Montino F, Pagliarulo M, et al. Comparison of the kinetics of intestinal colonization by associating 5 probiotic bacteria assumed either in a microencapsulated or in a traditional, uncoated form.
J Clin Gastroenterol
. 2012 Oct;46(suppl):S85–92.
18.
Fu G, Zhao K, Chen H, Wang Y, Nie L, Wei H, et al. Effect of 3 lactobacilli on immunoregulation and intestinal microbiota in a β-lactoglobulin-induced allergic mouse model.
J Dairy Sci
. 2019 Mar;102(3):1943–58.
19.
Yang SJ, Lee JE, Lim SM, Kim YJ, Lee NK, Paik HD. Antioxidant and immune-enhancing effects of probiotic Lactobacillus plantarum 200655 isolated from kimchi.
Food Sci Biotechnol
. 2018 Sep;28(2):491–9.
20.
Noguchi S, Hattori M, Sugiyama H, Hanaoka A, Okada S, Yoshida T. Lactobacillus plantarum NRIC1832 enhances IL-10 production from CD4+ T cells in vitro. Biosci Biotechnol Biochem. 2012;76(10):1925–31.
21.
Ma X, Yan W, Zheng H, Du Q, Zhang L, Ban Y, et al. Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells. F1000Res. 2015 Dec 17;4.
22.
Mogna L, Pane M, Nicola S, Raiteri E. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans?
J Clin Gastroenterol
. 2014 Nov-Dec;48(suppl 1):S91–5.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.